Hoth Therapeutics HOTH 深 沪
等待开盘 12-19 09:30:00 美东时间
1.07
0.000
0.00%
华盛通- 最 高1.12
- 今 开1.08
- 成交量 11.84万股
- 最 低 1.07
- 昨 收 1.07
- 总市值 1418.71万
- 52周最高 3.80
- 市盈率 静 --
- 换手率 0.89%
- 52周最低 0.6554
- 委 比 15.04%
- 总股本 1325.90万
- 历史最高 347.00
- 量 比 0.91
- 振 幅 4.67%
- 历史最低 0.58
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Lexaria Bioscience (NASDAQ:LEXX) stock increased by 6.5% to $0.89 durin...
12-17 05:05
Hoth Therapeutics Reports Pipeline Progress Across HT‑001, HT‑KIT, HT‑ALZ And New GDNF Program, Expands IP Portfolio And Partnerships
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful progress across HT-001,
12-04 03:04
Hoth Therapeutics Joins NVIDIA Connect Program To Accelerate AI-Driven Drug Development
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has been officially accepted into the NVIDIA Connect Program, a
11-20 21:14
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
D. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.
11-17 21:11
Hoth Therapeutics shares are trading higher after the company announced FDA Orphan Drug designation and preclinical data for HT-KIT in rare C-KIT-driven cancers
Hoth Therapeutics shares are trading higher after the company announced FDA Orp...
10-21 20:28
Hoth Therapeutics Prepares Presentation on October 17, 2025
Hoth Therapeutics ( ($HOTH) ) has shared an update. Hoth Therapeutics announced...
10-18 04:50
Hoth Therapeutics Expands Its AI Initiative Through Nvidia AI Enterprise Subscription License
Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling
10-08 22:24
Hoth Therapeutics To Present HT-001 And HT-KIT Oncology Programs At BIO-Europe 2025
Presentation to highlight advancements in Hoth's clinical pipeline, includingHT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology programtargeting KIT-driven tumorsNEW YORK, Oct. 7, 2025 /PRNewswire/
10-07 20:00
Hoth Therapeutics Expands Intellectual Property Portfolio For HT-001 With New U.S. Provisional Patent Filings Covering Novel Dermatological Indications
MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address
09-24 20:16
